Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1
The human appetite has more than one off switch, and drugmakers like Eli Lilly (LLY +0.76%) and Novo Nordisk (NVO 2.31%) are doing their darndest to identify and develop a medicine to target every single one. On June 24, Viking Therapeutics (VKTX +1.95%) announced a phase 1 trial for one of its candidates that’s attempting…